Go to deals

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a Phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

Funding, debt advisory & ECM
“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraise and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Talk to the deal team

 Geoff  Nash

Geoff Nash


London, United Kingdom
Oaklins Cavendish

Related deals

Spring has completed an equity raise
Real Estate

Spring has completed an equity raise

The owners and management of Spring have completed a fundraising to support its growth strategy.

Learn more
CML Group (ASX:CGR) has completed a placement
Financial Services

CML Group (ASX:CGR) has completed a placement

CML Group (ASX:CGR) has completed a US$2.5 million placement. The raise was completed at an issue price of US$0.238 (A$0.328) per share to institutional and professional investors. Funds raised will be used to support the company’s cash position to fund growth in its loan book.

Learn more
GBM Resources (ASX:GBZ) has successfully raised US$4.6 million
Other Industries

GBM Resources (ASX:GBZ) has successfully raised US$4.6 million

GBM Resources Ltd. (ASX:GBZ) has completed a fundraising to accelerate development.

Learn more